JP2012527459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012527459A5 JP2012527459A5 JP2012511816A JP2012511816A JP2012527459A5 JP 2012527459 A5 JP2012527459 A5 JP 2012527459A5 JP 2012511816 A JP2012511816 A JP 2012511816A JP 2012511816 A JP2012511816 A JP 2012511816A JP 2012527459 A5 JP2012527459 A5 JP 2012527459A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- creutzfeldt
- jakob disease
- rap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 238000000034 method Methods 0.000 claims 13
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 12
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims 8
- 208000019715 inherited Creutzfeldt-Jakob disease Diseases 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 241001465754 Metazoa Species 0.000 claims 6
- 208000014644 Brain disease Diseases 0.000 claims 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 4
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 4
- 208000032274 Encephalopathy Diseases 0.000 claims 4
- 208000024777 Prion disease Diseases 0.000 claims 4
- 208000002704 Sporadic Creutzfeldt-Jakob disease Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000027488 iatrogenic Creutzfeldt-Jakob disease Diseases 0.000 claims 4
- 241000772415 Neovison vison Species 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 241000282943 Odocoileus Species 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000037957 feline spongiform encephalopathy Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 206010023497 kuru Diseases 0.000 claims 2
- 231100000518 lethal Toxicity 0.000 claims 2
- 230000001665 lethal effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000008864 scrapie Diseases 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 241000282979 Alces alces Species 0.000 claims 1
- 241000283726 Bison Species 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 claims 1
- 241000282817 Bovidae Species 0.000 claims 1
- 241000195940 Bryophyta Species 0.000 claims 1
- 241000283707 Capra Species 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- 241001502386 Hippotragus leucophaeus Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241000283870 Oryx gazella Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 239000008135 aqueous vehicle Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940082150 encore Drugs 0.000 claims 1
- 230000003628 erosive effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 235000011929 mousse Nutrition 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18040609P | 2009-05-21 | 2009-05-21 | |
| US61/180,406 | 2009-05-21 | ||
| US21875209P | 2009-06-19 | 2009-06-19 | |
| US61/218,752 | 2009-06-19 | ||
| PCT/US2010/001455 WO2010134970A1 (en) | 2009-05-21 | 2010-05-17 | Inhibition of prion protein propagation by receptor associated protein (rap). its derivatives, mimetics and syntentic peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012527459A JP2012527459A (ja) | 2012-11-08 |
| JP2012527459A5 true JP2012527459A5 (enExample) | 2013-07-04 |
| JP5862560B2 JP5862560B2 (ja) | 2016-02-16 |
Family
ID=43126428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511816A Expired - Fee Related JP5862560B2 (ja) | 2009-05-21 | 2010-05-17 | レセプター随伴タンパク質（ｒａｐ）、前記の誘導体、模倣体および合成ペプチドによるプリオン増殖の阻害 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9051390B2 (enExample) |
| EP (1) | EP2432487B1 (enExample) |
| JP (1) | JP5862560B2 (enExample) |
| AU (1) | AU2010250104B2 (enExample) |
| CA (1) | CA2755948A1 (enExample) |
| WO (1) | WO2010134970A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017218897A1 (en) * | 2016-06-17 | 2017-12-21 | The Trustees Of The University Of Pennsylvania | Novel 1gg binding peptides and multifunctional antigen-binding proteins comprising the same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110938A1 (en) * | 2000-02-24 | 2004-06-10 | Parekh Rajesh Bhikhu | Proteins, genes and their use for diagnosis and treatment of schizophrenia |
| PT1953551E (pt) * | 2002-12-03 | 2014-05-06 | Pathogen Removal & Diagnostic Technologies Inc | Ligandos a proteína de prião e métodos de uso |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| EP1638605B1 (en) | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
-
2010
- 2010-05-17 WO PCT/US2010/001455 patent/WO2010134970A1/en not_active Ceased
- 2010-05-17 JP JP2012511816A patent/JP5862560B2/ja not_active Expired - Fee Related
- 2010-05-17 US US13/265,242 patent/US9051390B2/en not_active Expired - Fee Related
- 2010-05-17 CA CA2755948A patent/CA2755948A1/en not_active Abandoned
- 2010-05-17 AU AU2010250104A patent/AU2010250104B2/en not_active Ceased
- 2010-05-17 EP EP10778035.5A patent/EP2432487B1/en not_active Not-in-force
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Autophagy in neuroinflammation: a focus on epigenetic regulation | |
| Butterworth | Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure | |
| US8987199B2 (en) | Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders | |
| US12144798B2 (en) | (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8ahexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration | |
| Maiese | Cutting through the complexities of mTOR for the treatment of stroke | |
| Chen et al. | Carbon monoxide ameliorates acetaminophen‐induced liver injury by increasing hepatic HO‐1 and Parkin expression | |
| Nagayach et al. | Autophagy in neural stem cells and glia for brain health and diseases | |
| Abdulrahman et al. | Combining autophagy stimulators and cellulose ethers for therapy against prion disease | |
| EP2515929A1 (en) | Methods and use related to humanin and humanin-like peptides | |
| Jiao et al. | The autophagy–lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson’s disease | |
| WO2021158941A1 (en) | Nitric oxide-releasing antibacterial compounds, formulations, and methods pertaining thereto | |
| CN111655267A (zh) | 预防或治疗鼻病毒感染的药物 | |
| JP2019501167A5 (enExample) | ||
| Yassaghi et al. | Microglial modulation as a therapeutic strategy in Alzheimer's disease: Focus on microglial preconditioning approaches | |
| Zhang et al. | The role of amyloid β in the pathological mechanism of GNE myopathy | |
| JP2012527459A5 (enExample) | ||
| Nordström et al. | Inhibitors of the mitogen-activated protein kinase kinase 1/2 signaling pathway clear prion-infected cells from PrPSc | |
| CN115697301A (zh) | 用于治疗急性呼吸窘迫综合征、哮喘或变应性鼻炎的制剂和方法 | |
| US20210060060A1 (en) | Compositions and methods for the treatment of lung emphysema and other forms of copd | |
| US12551533B2 (en) | Intranasal neuropeptides for use in stress-related impairments | |
| WO2012156310A1 (en) | Novel peptides | |
| JP2023537589A (ja) | 治療剤の標的化送達 | |
| Bhattacharya et al. | Neuroinflammation and Its Impact on Autophagy in Neurodegeneration | |
| JP5862560B2 (ja) | レセプター随伴タンパク質（ｒａｐ）、前記の誘導体、模倣体および合成ペプチドによるプリオン増殖の阻害 | |
| WO2011151330A1 (en) | 1-(2-fluorobiphenyl-4-yl)-cyclopropanecarboxylic acid derivatives for the therapy of prion diseases |